Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 4/2014

Open Access 01-08-2014 | Review

Albumin administration in the acutely ill: what is new and where next?

Authors: Jean-Louis Vincent, James A Russell, Matthias Jacob, Greg Martin, Bertrand Guidet, Jan Wernerman, Ricard Ferrer Roca, Stuart A McCluskey, Luciano Gattinoni

Published in: Critical Care | Issue 4/2014

Login to get access

Abstract

Albumin solutions have been used worldwide for the treatment of critically ill patients since they became commercially available in the 1940s. However, their use has become the subject of criticism and debate in more recent years. Importantly, all fluid solutions have potential benefits and drawbacks. Large multicenter randomized studies have provided valuable data regarding the safety of albumin solutions, and have begun to clarify which groups of patients are most likely to benefit from their use. However, many questions remain related to where exactly albumin fits within our fluid choices. Here, we briefly summarize some of the physiology and history of albumin use in intensive care before offering some evidence-based guidance for albumin use in critically ill patients.
Appendix
Available only for authorised users
Literature
1.
Ancell H: Course of lectures on the physiology and pathology of the blood, and other animal fluids. Lancet. 1839, 33: 222-231.CrossRef
2.
Cochrane Injuries Group Albumin Reviewers: Human albumin administration in critically ill patients: systematic review of randomised controlled trials. BMJ. 1998, 317: 235-240. 10.1136/bmj.317.7153.235.CrossRef
3.
Vincent JL: Relevance of albumin in modern critical care medicine. Best Pract Res Clin Anaesthesiol. 2009, 23: 183-191. 10.1016/j.bpa.2008.11.004.CrossRefPubMed
4.
Finfer S, Bellomo R, McEvoy S, Lo SK, Myburgh J, Neal B, Norton R: Effect of baseline serum albumin concentration on outcome of resuscitation with albumin or saline in patients in intensive care units: analysis of data from the saline versus albumin fluid evaluation (SAFE) study. BMJ. 2006, 333: 1044-CrossRefPubMed
5.
Vincent JL, Dubois MJ, Navickis RJ, Wilkes MM: Hypoalbuminemia in acute illness: is there a rationale for intervention? A meta-analysis of cohort studies and controlled trials. Ann Surg. 2003, 237: 319-334.PubMedCentralPubMed
6.
Laxenaire MC, Charpentier C, Feldman L: Anaphylactoid reactions to colloid plasma substitutes: incidence, risk factors, mechanisms. A French multicenter prospective study. Ann Fr Anesth Reanim. 1994, 13: 301-310. 10.1016/S0750-7658(94)80038-3.CrossRefPubMed
7.
McClelland DB: Safety of human albumin as a constituent of biologic therapeutic products. Transfusion. 1998, 38: 690-699. 10.1046/j.1537-2995.1998.38798346639.x.CrossRefPubMed
8.
American Thoracic Society: Evidence-based colloid use in the critically ill: American Thoracic Society Consensus Statement. Am J Respir Crit Care Med. 2004, 170: 1247-1259.CrossRef
9.
Peters T: All About Albumin. 1995, San Diego: Academic Press
10.
Fanali G, di Masi A, Trezza V, Marino M, Fasano M, Ascenzi P: Human serum albumin: from bench to bedside. Mol Aspects Med. 2012, 33: 209-290. 10.1016/j.mam.2011.12.002.CrossRefPubMed
11.
12.
Matejtschuk P, Dash CH, Gascoigne EW: Production of human albumin solution: a continually developing colloid. Br J Anaesth. 2000, 85: 887-895. 10.1093/bja/85.6.887.CrossRefPubMed
13.
Nicholson JP, Wolmarans MR, Park GR: The role of albumin in critical illness. Br J Anaesth. 2000, 85: 599-610. 10.1093/bja/85.4.599.CrossRefPubMed
14.
Fleck A, Raines G, Hawker F, Trotter J, Wallace PI, Ledingham IM, Calman KC: Increased vascular permeability: a major cause of hypoalbuminaemia in disease and injury. Lancet. 1985, 1: 781-784.CrossRefPubMed
15.
Margarson MP, Soni N: Serum albumin: touchstone or totem?. Anaesthesia. 1998, 53: 789-803. 10.1046/j.1365-2044.1998.00438.x.CrossRefPubMed
16.
Woodcock TE, Woodcock TM: Revised Starling equation and the glycocalyx model of transvascular fluid exchange: an improved paradigm for prescribing intravenous fluid therapy. Br J Anaesth. 2012, 108: 384-394. 10.1093/bja/aer515.CrossRefPubMed
17.
Jacob M, Bruegger D, Rehm M, Stoeckelhuber M, Welsch U, Conzen P, Becker BF: The endothelial glycocalyx affords compatibility of Starling's principle and high cardiac interstitial albumin levels. Cardiovasc Res. 2007, 73: 575-586. 10.1016/j.cardiores.2006.11.021.CrossRefPubMed
18.
Adamson RH, Lenz JF, Zhang X, Adamson GN, Weinbaum S, Curry FE: Oncotic pressures opposing filtration across non-fenestrated rat microvessels. J Physiol. 2004, 557: 889-907. 10.1113/jphysiol.2003.058255.PubMedCentralCrossRefPubMed
19.
Jacob M, Bruegger D, Rehm M, Welsch U, Conzen P, Becker BF: Contrasting effects of colloid and crystalloid resuscitation fluids on cardiac vascular permeability. Anesthesiology. 2006, 104: 1223-1231. 10.1097/00000542-200606000-00018.CrossRefPubMed
20.
Pries AR, Secomb TW, Gaehtgens P: The endothelial surface layer. Pflugers Arch. 2000, 440: 653-666. 10.1007/s004240000307.CrossRefPubMed
21.
Zausig YA, Chappell D, Becker BF, Potschka D, Busse H, Nixdorf K, Bitzinger D, Jacob B, Jacob M: The impact of crystalloidal and colloidal infusion preparations on coronary vascular integrity, interstitial oedema and cardiac performance in isolated hearts. Crit Care. 2013, 17: R203-10.1186/cc12898.PubMedCentralCrossRefPubMed
22.
Chappell D, Westphal M, Jacob M: The impact of the glycocalyx on microcirculatory oxygen distribution in critical illness. Curr Opin Anaesthesiol. 2009, 22: 155-162. 10.1097/ACO.0b013e328328d1b6.CrossRefPubMed
23.
Jacob M, Chappell D: Reappraising Starling: the physiology of the microcirculation. Curr Opin Crit Care. 2013, 19: 282-289. 10.1097/MCC.0b013e3283632d5e.CrossRefPubMed
24.
Roche M, Rondeau P, Singh NR, Tarnus E, Bourdon E: The antioxidant properties of serum albumin. FEBS Lett. 2008, 582: 1783-1787. 10.1016/j.febslet.2008.04.057.CrossRefPubMed
25.
Oettl K, Stauber RE: Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties. Br J Pharmacol. 2007, 151: 580-590. 10.1038/sj.bjp.0707251.PubMedCentralCrossRefPubMed
26.
27.
Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J: The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet. 2011, 50: 99-110. 10.2165/11539220-000000000-00000.CrossRefPubMed
28.
Figge J, Rossing TH, Fencl V: The role of serum proteins in acid–base equilibria. J Lab Clin Med. 1991, 117: 453-467.PubMed
29.
Jorgensen KA, Stoffersen E: On the inhibitory effect of albumin on platelet aggregation. Thromb Res. 1980, 17: 13-18. 10.1016/0049-3848(80)90289-3.CrossRefPubMed
30.
Dubois MJ, Orellana-Jimenez C, Melot C, De Backer D, Berre J, Leeman M, Brimioulle S, Appoloni O, Creteur J, Vincent JL: Albumin administration improves organ function in critically ill hypoalbuminemic patients: a prospective, randomized, controlled, pilot study. Crit Care Med. 2006, 34: 2536-2540. 10.1097/01.CCM.0000239119.57544.0C.CrossRefPubMed
31.
Redelmeier DA: New thinking about postoperative hypoalbuminemia: a hypothesis of occult protein-losing enteropathy. Open Med. 2009, 3: e215-e219.PubMedCentralPubMed
32.
Caironi P, Gattinoni L: The clinical use of albumin: the point of view of a specialist in intensive care. Blood Transfus. 2009, 7: 259-267.PubMedCentralPubMed
33.
Moshage HJ, Janssen JA, Franssen JH, Hafkenscheid JC, Yap SH: Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation. J Clin Invest. 1987, 79: 1635-1641. 10.1172/JCI113000.PubMedCentralCrossRefPubMed
34.
Barle H, Hammarqvist F, Westman B, Klaude M, Rooyackers O, Garlick PJ, Wernerman J: Synthesis rates of total liver protein and albumin are both increased in patients with an acute inflammatory response. Clin Sci (Lond). 2006, 110: 93-99. 10.1042/CS20050222.CrossRef
35.
Serra R, Caroleo S, Buffone G, Lugara M, Molinari V, Tropea F, Amantea B, de Franciscis S: Low serum albumin level as an independent risk factor for the onset of pressure ulcers in intensive care unit patients. Int Wound J. 2012, doi: 10.1111/iwj.12004
36.
Al-Subaie N, Reynolds T, Myers A, Sunderland R, Rhodes A, Grounds RM, Hall GM: C-reactive protein as a predictor of outcome after discharge from the intensive care: a prospective observational study. Br J Anaesth. 2010, 105: 318-325. 10.1093/bja/aeq171.CrossRefPubMed
37.
Wiedermann CJ, Wiedermann W, Joannidis M: Hypoalbuminemia and acute kidney injury: a meta-analysis of observational clinical studies. Intensive Care Med. 2010, 36: 1657-1665. 10.1007/s00134-010-1928-z.CrossRefPubMed
38.
Lee EH, Baek SH, Chin JH, Choi DK, Son HJ, Kim WJ, Hahm KD, Sim JY, Choi IC: Preoperative hypoalbuminemia is a major risk factor for acute kidney injury following off-pump coronary artery bypass surgery. Intensive Care Med. 2012, 38: 1478-1486. 10.1007/s00134-012-2599-8.CrossRefPubMed
39.
Lyons O, Whelan B, Bennett K, O'Riordan D, Silke B: Serum albumin as an outcome predictor in hospital emergency medical admissions. Eur J Intern Med. 2010, 21: 17-20. 10.1016/j.ejim.2009.10.010.CrossRefPubMed
40.
Bernard F, Al-Tamimi YZ, Chatfield D, Lynch AG, Matta BF, Menon DK: Serum albumin level as a predictor of outcome in traumatic brain injury: potential for treatment. J Trauma. 2008, 64: 872-875. 10.1097/TA.0b013e31803428cc.CrossRefPubMed
41.
Namendys-Silva SA, Gonzalez-Herrera MO, Texcocano-Becerra J, Herrera-Gomez A: Hypoalbuminemia in critically ill patients with cancer: incidence and mortality. Am J Hosp Palliat Care. 2011, 28: 253-257. 10.1177/1049909110384841.CrossRefPubMed
42.
de la Cruz KI, Bakaeen FG, Wang XL, Huh J, LeMaire SA, Coselli JS, Chu D: Hypoalbuminemia and long-term survival after coronary artery bypass: a propensity score analysis. Ann Thorac Surg. 2011, 91: 671-675. 10.1016/j.athoracsur.2010.09.004.CrossRefPubMed
43.
Artero A, Zaragoza R, Camarena JJ, Sancho S, Gonzalez R, Nogueira JM: Prognostic factors of mortality in patients with community-acquired bloodstream infection with severe sepsis and septic shock. J Crit Care. 2010, 25: 276-281. 10.1016/j.jcrc.2009.12.004.CrossRefPubMed
44.
Ranzani OT, Zampieri FG, Forte DN, Azevedo LC, Park M: C-reactive protein/albumin ratio predicts 90-day mortality of septic patients. PLoS One. 2013, 8: e59321-10.1371/journal.pone.0059321.PubMedCentralCrossRefPubMed
45.
Gibbs J, Cull W, Henderson W, Daley J, Hur K, Khuri SF: Preoperative serum albumin level as a predictor of operative mortality and morbidity: results from the National VA Surgical Risk Study. Arch Surg. 1999, 134: 36-42. 10.1001/archsurg.134.1.36.CrossRefPubMed
46.
Skillman JJ, Restall DS, Salzman EW: Randomized trial of albumin vs. electrolyte solutions during abdominal aortic operations. Surgery. 1975, 78: 291-303.PubMed
47.
Roberts I, Edwards P, McLelland B: More on albumin. Use of human albumin in UK fell substantially when systematic review was published. BMJ. 1999, 318: 1214-1215.PubMedCentralCrossRefPubMed
48.
CSM Expert Working Party: The safety of human albumin. Curr Probl Pharmacovigilance. 1999, 25: 11-
49.
Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R: A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004, 350: 2247-2256.CrossRefPubMed
50.
Woodruff LM, Gibson ST: The clinical evaluation of human albumin. US Naval Med Bull. 1942, 40: 791-796.
51.
52.
Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, Castells L, Vargas V, Soriano G, Guevara M, Gines P, Rodes J: Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999, 341: 403-409. 10.1056/NEJM199908053410603.CrossRefPubMed
53.
Wilkes MM, Navickis RJ: Patient survival after human albumin administration. A meta-analysis of randomized, controlled trials. Ann Intern Med. 2001, 135: 149-164. 10.7326/0003-4819-135-3-200108070-00007.CrossRefPubMed
54.
Finfer S, McEvoy S, Bellomo R, McArthur C, Myburgh J, Norton R: Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis. Intensive Care Med. 2011, 37: 86-96.CrossRefPubMed
55.
Myburgh J, Cooper DJ, Finfer S, Bellomo R, Norton R, Bishop N, Kai LS, Vallance S: Saline or albumin for fluid resuscitation in patients with traumatic brain injury. N Engl J Med. 2007, 357: 874-884.CrossRefPubMed
56.
57.
Vincent JL, Sakr Y, Reinhart K, Sprung CL, Gerlach H, Ranieri VM: Is albumin administration in the acutely ill associated with increased mortality? Results of the SOAP study. Crit Care. 2005, 9: R745-R754. 10.1186/cc3895.PubMedCentralCrossRefPubMed
58.
Delaney AP, Dan A, McCaffrey J, Finfer S: The role of albumin as a resuscitation fluid for patients with sepsis: a systematic review and meta-analysis. Crit Care Med. 2011, 39: 386-391. 10.1097/CCM.0b013e3181ffe217.CrossRefPubMed
59.
Reinhart K, Perner A, Sprung CL, Jaeschke R, Schortgen F, Johan Groeneveld AB, Beale R, Hartog CS: Consensus statement of the ESICM task force on colloid volume therapy in critically ill patients. Intensive Care Med. 2012, 38: 368-383. 10.1007/s00134-012-2472-9.CrossRefPubMed
60.
Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R: Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013, 41: 580-637. 10.1097/CCM.0b013e31827e83af.CrossRefPubMed
61.
Charpentier J, Mira JP, EARSS Study Group: Efficacy and tolerance of hyperoncotic albumin administration in septic shock patients: the EARSS study [abstract]. Intensive Care Med. 2011, 37 (Suppl 2): S115-0438.
62.
Caironi P, Tognoni G, Masson S, Fumagalli R, Pesenti A, Romero M, Fanizza C, Caspani L, Faenza S, Grasselli G, Iapichino G, Antonelli M, Parrini V, Fiore G, Latini R, Gattinoni L: Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med. 2014, 370: 1412-1421. 10.1056/NEJMoa1305727.CrossRefPubMed
63.
Cooper DJ, Myburgh J, Heritier S, Finfer S, Bellomo R, Billot L, Murray L, Vallance S: Albumin resuscitation for traumatic brain injury: is intracranial hypertension the cause of increased mortality?. J Neurotrauma. 2013, 30: 512-518. 10.1089/neu.2012.2573.PubMedCentralCrossRefPubMed
64.
Van Aken HK, Kampmeier TG, Ertmer C, Westphal M: Fluid resuscitation in patients with traumatic brain injury: what is a SAFE approach?. Curr Opin Anaesthesiol. 2012, 25: 563-565. 10.1097/ACO.0b013e3283572274.CrossRefPubMed
65.
Martin GS, Mangialardi RJ, Wheeler AP, Dupont WD, Morris JA, Bernard GR: Albumin and furosemide therapy in hypoproteinemic patients with acute lung injury. Crit Care Med. 2002, 30: 2175-2182. 10.1097/00003246-200210000-00001.CrossRefPubMed
66.
Martin GS, Moss M, Wheeler AP, Mealer M, Morris JA, Bernard GR: A randomized, controlled trial of furosemide with or without albumin in hypoproteinemic patients with acute lung injury. Crit Care Med. 2005, 33: 1681-1687. 10.1097/01.CCM.0000171539.47006.02.CrossRefPubMed
67.
Gentilini P, Casini-Raggi V, Di Fiore G, Romanelli RG, Buzzelli G, Pinzani M, La Villa G, Laffi G: Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J Hepatol. 1999, 30: 639-645. 10.1016/S0168-8278(99)80194-9.CrossRefPubMed
68.
Doungngern T, Huckleberry Y, Bloom JW, Erstad B: Effect of albumin on diuretic response to furosemide in patients with hypoalbuminemia. Am J Crit Care. 2012, 21: 280-286. 10.4037/ajcc2012999.CrossRefPubMed
69.
Guevara M, Terra C, Nazar A, Sola E, Fernandez J, Pavesi M, Arroyo V, Gines P: Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study. J Hepatol. 2012, 57: 759-765. 10.1016/j.jhep.2012.06.013.CrossRefPubMed
70.
Kwok CS, Krupa L, Mahtani A, Kaye D, Rushbrook SM, Phillips MG, Gelson W: Albumin reduces paracentesis-induced circulatory dysfunction and reduces death and renal impairment among patients with cirrhosis and infection: a systematic review and meta-analysis. Biomed Res Int. 2013, 2013: 295153-PubMedCentralPubMed
71.
Martin-Llahi M, Pepin MN, Guevara M, Diaz F, Torre A, Monescillo A, Soriano G, Terra C, Fabrega E, Arroyo V, Rodes J, Gines P: Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology. 2008, 134: 1352-1359. 10.1053/j.gastro.2008.02.024.CrossRefPubMed
72.
Neri S, Pulvirenti D, Malaguarnera M, Cosimo BM, Bertino G, Ignaccolo L, Siringo S, Castellino P: Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci. 2008, 53: 830-835. 10.1007/s10620-007-9919-9.CrossRefPubMed
73.
Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001, 345: 1368-1377. 10.1056/NEJMoa010307.CrossRefPubMed
74.
Wiedermann CJ, Joannidis M: Accumulation of hydroxyethyl starch in human and animal tissues: a systematic review. Intensive Care Med. 2014, 40: 160-170. 10.1007/s00134-013-3156-9.CrossRefPubMed
75.
Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Aneman A, Madsen KR, Moller MH, Elkjaer JM, Poulsen LM, Bendtsen A, Winding R, Steensen M, Berezowicz P, Soe-Jensen P, Bestle M, Strand K, Wiis J, White JO, Thornberg KJ, Quist L, Nielsen J, Andersen LH, Holst LB, Thormar K, Kjaeldgaard AL, Fabritius ML, Mondrup F, Pott FC, Moller TP, et al: Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med. 2012, 367: 124-134. 10.1056/NEJMoa1204242.CrossRefPubMed
76.
Rehm M, Orth V, Kreimeier U, Thiel M, Haller M, Brechtelsbauer H, Finsterer U: Changes in intravascular volume during acute normovolemic hemodilution and intraoperative retransfusion in patients with radical hysterectomy. Anesthesiology. 2000, 92: 657-664. 10.1097/00000542-200003000-00008.CrossRefPubMed
77.
Jacob M, Chappell D, Hofmann-Kiefer K, Helfen T, Schuelke A, Jacob B, Burges A, Conzen P, Rehm M: The intravascular volume effect of Ringer's lactate is below 20%: a prospective study in humans. Crit Care. 2012, 16: R86-10.1186/cc11344.PubMedCentralCrossRefPubMed
78.
Yunos NM, Bellomo R, Hegarty C, Story D, Ho L, Bailey M: Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA. 2012, 308: 1566-1572. 10.1001/jama.2012.13356.CrossRefPubMed
79.
Ernest D, Belzberg AS, Dodek PM: Distribution of normal saline and 5% albumin infusions in septic patients. Crit Care Med. 1999, 27: 46-50. 10.1097/00003246-199901000-00025.CrossRefPubMed
80.
Farrugia A: Albumin usage in clinical medicine: tradition or therapeutic?. Transfus Med Rev. 2010, 24: 53-63. 10.1016/j.tmrv.2009.09.005.CrossRefPubMed
81.
Bar-Or D, Bar-Or R, Rael LT, Gardner DK, Slone DS, Craun ML: Heterogeneity and oxidation status of commercial human albumin preparations in clinical use. Crit Care Med. 2005, 33: 1638-1641. 10.1097/01.CCM.0000169876.14858.91.CrossRefPubMed
82.
Martin GS: Pharmacological aspects of albumin as a niche product in the intensive care unit. Crit Care Med. 2005, 33: 1667-1669. 10.1097/01.CCM.0000170175.18540.CD.CrossRefPubMed
83.
Vincent JL, Wilkes MM, Navickis RJ: Safety of human albumin – serious adverse events reported worldwide in 1998–2000. Br J Anaesth. 2003, 91: 625-630. 10.1093/bja/aeg233.CrossRefPubMed
84.
Barron ME, Wilkes MM, Navickis RJ: A systematic review of the comparative safety of colloids. Arch Surg. 2004, 139: 552-563. 10.1001/archsurg.139.5.552.CrossRefPubMed
85.
Groeneveld AB, Navickis RJ, Wilkes MM: Update on the comparative safety of colloids: a systematic review of clinical studies. Ann Surg. 2011, 253: 470-483. 10.1097/SLA.0b013e318202ff00.CrossRefPubMed
86.
Guidet B, Mosqueda GJ, Priol G, Aegerter P: The COASST study: cost-effectiveness of albumin in severe sepsis and septic shock. J Crit Care. 2007, 22: 197-203. 10.1016/j.jcrc.2006.11.005.CrossRefPubMed
87.
Farrugia A, Bansal M, Balboni S, Kimber MC, Martin GS, Cassar J: Choice of fluids in severe septic patients – a cost-effectiveness analysis informed by recent clinical trials. Rev Recent Clin Trials. 2013, [Epub ahead of print]
88.
Vincent JL, Fink MP, Marini JJ, Pinsky MR, Sibbald WJ, Singer M, Suter PM, Cook D, Pepe PE, Evans T: Intensive care and emergency medicine: progress over the past 25 years. Chest. 2006, 129: 1061-1067. 10.1378/chest.129.4.1061.CrossRefPubMed
89.
Salerno F, Gerbes A, Gines P, Wong F, Arroyo V: Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007, 56: 1310-1318.PubMedCentralPubMed
Metadata
Title
Albumin administration in the acutely ill: what is new and where next?
Authors
Jean-Louis Vincent
James A Russell
Matthias Jacob
Greg Martin
Bertrand Guidet
Jan Wernerman
Ricard Ferrer Roca
Stuart A McCluskey
Luciano Gattinoni
Publication date
01-08-2014
Publisher
BioMed Central
Published in
Critical Care / Issue 4/2014
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc13991

Other articles of this Issue 4/2014

Critical Care 4/2014 Go to the issue

Research

Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study

Research

Silencing airway epithelial cell-derived hepcidin exacerbates sepsis-induced acute lung injury

Research

A new device for continuous assessment of gut perfusion: proof of concept on a porcine model of septic shock

Research

Mortality of patients infected with HIV in the intensive care unit (2005 through 2010): significant role of chronic hepatitis C and severe sepsis

Research

Hypertonic sodium lactate improves fluid balance and hemodynamics in porcine endotoxic shock

Viewpoint

Conservative fluid therapy in septic shock: an example of targeted therapeutic minimization